AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biotage

Declaration of Voting Results & Voting Rights Announcements Jul 31, 2023

2894_rns_2023-07-31_3976cab1-3449-4dcd-8859-2ff133fe106c.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Change in number of votes

As previously announced, Biotage AB (publ) ("Biotage") has during July 2023 re-classified 70,307 class C shares to 70,307 ordinary shares in connection with the completion of the longterm incentive plan adopted on the Annual General Meeting 2020 ("LTIP 2020"). The reclassification was carried out by Biotage in order to (i) deliver ordinary shares to participants in LTIP 2020 and (ii) sell ordinary shares in the market in order to cover social contributions arising as a result of LTIP 2020.

Prior to the re-classification, the total number of outstanding shares in Biotage amounted to 80,667,695 and the total number of votes amounted to 80,010,859.7. Through the re-classification, the total number of votes in Biotage has increased by 63,276.3 while the total number of shares remain unchanged. As of today, the last trading day of the month, the total number of registered shares in Biotage amounts to 80,667,695, whereof 80,008,185 are ordinary shares and 659,510 are class C shares held by Biotage. As of today, the number of votes in Biotage amounts to 80,074,136, and the registered share capital amounts to SEK 112,128,096.05.

Contacts

Tomas Blomquist, President and CEO Tel: 0705 23 01 63, [email protected]

About Biotage

Biotage is a Global Impact Tech Company committed to solving society's problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world a healthier, greener and cleaner place – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs appr. 700 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage's share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm. Website: www.biotage.com

This information is information that Biotage is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-07-31 17:30 CEST.

Attachments

Change in number of votes

Talk to a Data Expert

Have a question? We'll get back to you promptly.